Kleiman, Neal

Publications

Sort by

Co-Author Network

selected publications

In-Hospital Outcomes with Transfemoral Versus Transapical Access for Transcatheter Aortic Valve Replacement in Patients with Peripheral Arterial Disease. Cardiovascular revascularization medicine : including molecular interventions. 2019 Academic Article GET IT
Times cited: 2
Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. JAMA. 2019 Academic Article GET IT
Times cited: 132
Too Thick to Cut With SISRs. Circulation. Cardiovascular interventions. 2018 Editorial Article GET IT
Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting. JACC. Cardiovascular interventions. 2018 Editorial Article GET IT
Delayed Coronary Obstruction After TAVR: A Call for Vigilance. Journal of the American College of Cardiology. 2018 Editorial Article GET IT
Times cited: 6
Bleeding Edge Technology: Retroperitoneal Hemorrhage and Its Implications for Transradial Access. Circulation. Cardiovascular interventions. 2018 Editorial Article GET IT
Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry. JAMA cardiology. 2017 Academic Article GET IT
Times cited: 60
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC. Cardiovascular interventions. 2017 Academic Article GET IT
Times cited: 65
Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center. The Journal of thoracic and cardiovascular surgery. 2017 Academic Article GET IT
Times cited: 32
Bioresorbable Scaffold: The Emerging Reality and Future Directions. Circulation research. 2017 Information Resource GET IT
Times cited: 82
At Arm's Length: Radiation Safety During Radial Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2017 Editorial Article GET IT
Times cited: 1
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 1361
New-Generation Coronary Stents: Current Data and Future Directions. Current atherosclerosis reports. 2017 Information Resource GET IT
Times cited: 28
One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. The Annals of thoracic surgery. 2017 Academic Article GET IT
Times cited: 7
SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. Journal of the American College of Cardiology. 2017 Academic Article GET IT
Times cited: 50
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2017 Academic Article GET IT
Times cited: 39
Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. Cardiovascular revascularization medicine : including molecular interventions. 2016 Academic Article GET IT
Times cited: 5
Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors: A Report From the CoreValve Trials. Circulation. Cardiovascular interventions. 2016 Academic Article GET IT
Times cited: 55
The Last Detail: Platelets, Glycoprotein IIb/IIIa Antagonists, and Excipients. JACC. Cardiovascular interventions. 2016 Editorial Article GET IT
Times cited: 2
Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call-to-action for optimal training of the next generation of interventionalists. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2016 Editorial Article GET IT
Times cited: 8
Highway to the heart or one more for the road? The continued life of direct aortic access for transcatheter aortic valve replacement. The Journal of thoracic and cardiovascular surgery. 2016 Editorial Article GET IT
Are Immature Platelets Growing Up?: Toward a New Marker of Antiplatelet Drug Resistance. Journal of the American College of Cardiology. 2016 Editorial Article GET IT
Times cited: 3
Detection and quantification of circulating immature platelets: agreement between flow cytometric and automated detection. Journal of thrombosis and thrombolysis. 2016 Academic Article GET IT
Times cited: 16
VWF, ADAMTS13, and acute coronary syndromes. Blood. 2016 Article GET IT
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement. Circulation. Cardiovascular interventions. 2016 Academic Article GET IT
Times cited: 29
Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). The American journal of cardiology. 2016 Academic Article GET IT
Times cited: 23
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 2016 Academic Article GET IT
Times cited: 219
Watching a Procedure Evolve: Sequential Findings From the TVT Registry. The Annals of thoracic surgery. 2015 Editorial Article GET IT
Times cited: 1
Watching a Procedure Evolve: Sequential Findings From the TVT Registry. Journal of the American College of Cardiology. 2015 Editorial Article GET IT
Times cited: 3
Vascular complication can be minimized with a balloon-expandable, re-collapsible sheath in TAVR with a self-expanding bioprosthesis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2015 Academic Article GET IT
Times cited: 7
Regression of Paravalvular Aortic Regurgitation and Remodeling of Self-Expanding Transcatheter Aortic Valve: An Observation From the CoreValve U.S. Pivotal Trial. JACC. Cardiovascular imaging. 2015 Academic Article GET IT
Times cited: 58
2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. Journal of the American College of Cardiology. 2015 Academic Article GET IT
Times cited: 44
Direct Aortic Access Transcatheter Aortic Valve Replacement: Three-Dimensional Computed Tomography Planning and Real-Time Fluoroscopic Image Guidance. The Journal of heart valve disease. 2015 Academic Article GET IT
Times cited: 8
Short-Term Outcomes with Direct Aortic Access for Transcatheter Aortic Valve Replacement. The Journal of heart valve disease. 2015 Academic Article GET IT
Times cited: 1
Expanding the Roster: Developing New Inhibitors of Intravascular Thrombosis. Journal of the American College of Cardiology. 2015 Editorial Article GET IT
Times cited: 4
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 2015 Academic Article GET IT
Times cited: 298
Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial. International journal of endocrinology. 2015 Academic Article GET IT
Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. JACC. Cardiovascular interventions. 2015 Academic Article GET IT
Times cited: 74
Association of immature platelets with adverse cardiovascular outcomes. Journal of the American College of Cardiology. 2014 Academic Article GET IT
Times cited: 79
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. The Journal of thoracic and cardiovascular surgery. 2014 Academic Article GET IT
Times cited: 55
Comparison of the use of hemodynamic support in patients ≥80 years versus patients <80 years during high-risk percutaneous coronary interventions (from the Multicenter PROTECT II Randomized Study). The American journal of cardiology. 2014 Academic Article GET IT
Times cited: 12
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. European heart journal. 2014 Academic Article GET IT
Times cited: 71
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Circulation. Cardiovascular interventions. 2014 Academic Article GET IT
Times cited: 12
Transcatheter aortic-valve replacement with a self-expanding prosthesis. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1763
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. Journal of the American College of Cardiology. 2014 Academic Article GET IT
Times cited: 700
Direct aortic and subclavian access for transcatheter aortic valve replacement: decision making and technique. The Journal of thoracic and cardiovascular surgery. 2014 Academic Article GET IT
Times cited: 14
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. American journal of physiology. Heart and circulatory physiology. 2013 Academic Article GET IT
Times cited: 23
Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). The American journal of cardiology. 2013 Academic Article GET IT
Times cited: 10
Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2013 Academic Article GET IT
Times cited: 24
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. American heart journal. 2013 Academic Article GET IT
Times cited: 15
Percutaneous placement of an intra-aortic balloon pump in the left axillary/subclavian position provides safe, ambulatory long-term support as bridge to heart transplantation. JACC. Heart failure. 2013 Academic Article GET IT
Times cited: 100
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and haemostasis. 2013 Academic Article GET IT
Times cited: 13
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC. Cardiovascular interventions. 2013 Academic Article GET IT
Times cited: 17
In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2013 Academic Article GET IT
Times cited: 4
Red cell distribution width as a bleeding predictor after percutaneous coronary intervention. American heart journal. 2013 Academic Article GET IT
Times cited: 18
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. International journal of cardiology. 2013 Academic Article GET IT
Times cited: 16
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention. Journal of thrombosis and thrombolysis. 2013 Academic Article GET IT
Times cited: 34
Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circulation. Cardiovascular interventions. 2012 Academic Article GET IT
Times cited: 38
A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012 Academic Article GET IT
Times cited: 434
Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo. Journal of thrombosis and thrombolysis. 2012 Academic Article GET IT
Times cited: 11
Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). The American journal of cardiology. 2012 Academic Article GET IT
Times cited: 23
In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2012 Academic Article GET IT
Times cited: 6
Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2012 Academic Article GET IT
Times cited: 98
Room considerations with TAVR. Methodist DeBakey cardiovascular journal. 2012 Academic Article GET IT
Times cited: 6
Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. Circulation. 2012 Editorial Article GET IT
Times cited: 14
Troponin criteria for myocardial infarction after percutaneous coronary intervention. Archives of internal medicine. 2012 Academic Article GET IT
Times cited: 91
Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. Journal of thrombosis and thrombolysis. 2012 Academic Article GET IT
Times cited: 42
Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. American heart journal. 2011 Academic Article GET IT
Times cited: 9
Survival benefit with drug-eluting stents in observational studies: fact or artifact?. Circulation. Cardiovascular quality and outcomes. 2011 Academic Article GET IT
Times cited: 26
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circulation. Cardiovascular interventions. 2011 Academic Article GET IT
Times cited: 20
Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circulation. Cardiovascular interventions. 2011 Academic Article GET IT
Times cited: 37
Balancing hemostasis and thrombosis in interventional vascular medicine and surgery. Methodist DeBakey cardiovascular journal. 2011 Information Resource GET IT
Bringing it all together: integration of physiology with anatomy during cardiac catheterization. Journal of the American College of Cardiology. 2011 Editorial Article GET IT
Times cited: 36
Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Circulation. 2011 Academic Article GET IT
Times cited: 32
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". American heart journal. 2011 Academic Article GET IT
Times cited: 23
Determinants of plasma vitamin D levels in patients with acute coronary syndromes. European journal of clinical investigation. 2011 Academic Article GET IT
Times cited: 8
The impact of postrandomization crossover of therapy in acute coronary syndromes care. Circulation. Cardiovascular quality and outcomes. 2011 Academic Article GET IT
Times cited: 4
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. Journal of thrombosis and thrombolysis. 2011 Academic Article GET IT
Times cited: 6
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. American heart journal. 2011 Academic Article GET IT
Times cited: 20
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemporary clinical trials. 2011 Academic Article GET IT
Times cited: 11
TAVI: transcatheter aortic valve implantation. Methodist DeBakey cardiovascular journal. 2011 Academic Article GET IT
ED to catheterization laboratory: a roundtable integrating trials with practice. The American journal of emergency medicine. 2010 Information Resource GET IT
Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. Journal of thrombosis and thrombolysis. 2010 Academic Article GET IT
Times cited: 73
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. American heart journal. 2010 Academic Article GET IT
Times cited: 11
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC. Cardiovascular interventions. 2010 Academic Article GET IT
Times cited: 117
Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circulation. Cardiovascular interventions. 2010 Academic Article GET IT
Times cited: 61
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2010 Academic Article GET IT
Times cited: 15
Resistance or resistors? Has Ohm's law come to antiplatelet therapy?. American heart journal. 2010 Editorial Article GET IT
Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation. 2010 Academic Article GET IT
Times cited: 18
Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. Journal of the American College of Cardiology. 2010 Academic Article GET IT
Times cited: 62
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). The American journal of cardiology. 2010 Academic Article GET IT
Times cited: 111
Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent. Journal of thrombosis and thrombolysis. 2010 Academic Article GET IT
Times cited: 9
Intravenous platelet blockade with cangrelor during PCI. The New England journal of medicine. 2009 Academic Article GET IT
Times cited: 519
Platelet inhibition with cangrelor in patients undergoing PCI. The New England journal of medicine. 2009 Academic Article GET IT
Times cited: 501
Impact of computerized dosing on eptifibatide-associated bleeding and mortality. American heart journal. 2009 Academic Article GET IT
Times cited: 1
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC. Cardiovascular interventions. 2009 Academic Article GET IT
Times cited: 70
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC. Cardiovascular interventions. 2009 Academic Article GET IT
Times cited: 13
Combining antiplatelet and anticoagulant therapies. Journal of the American College of Cardiology. 2009 Information Resource GET IT
Times cited: 136
Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2009 Academic Article GET IT
Times cited: 7
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. The American journal of cardiology. 2009 Information Resource GET IT
Times cited: 102
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European heart journal. 2009 Academic Article GET IT
Times cited: 116
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. American heart journal. 2009 Academic Article GET IT
Times cited: 39
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC. Cardiovascular interventions. 2009 Academic Article GET IT
Times cited: 120
Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?. Journal of the American College of Cardiology. 2008 Editorial Article GET IT
Times cited: 6
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. American heart journal. 2008 Academic Article GET IT
Times cited: 40
Three-dimensional transesophageal echocardiogram provides real-time guidance during percutaneous paravalvular mitral repair. 2008 GET IT
Times cited: 3
Vascular changes and black hole phenomenon after coronary brachytherapy: a pathologically distinct entity. The Journal of invasive cardiology. 2008 Information Resource GET IT
Times cited: 3
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. Journal of the American College of Cardiology. 2008 Academic Article GET IT
Times cited: 264
The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2008 Academic Article GET IT
Times cited: 32
Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation. 2008 Academic Article GET IT
Times cited: 58
Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thrombosis and haemostasis. 2008 Academic Article GET IT
Times cited: 23
Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets. 2008 Information Resource GET IT
Times cited: 12
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Academic Article GET IT
Times cited: 112
Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?. Journal of the American College of Cardiology. 2008 Editorial Article GET IT
Times cited: 13
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 Academic Article GET IT
Times cited: 147
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. Journal of general internal medicine. 2008 Academic Article GET IT
Times cited: 42
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Archives of internal medicine. 2008 Academic Article GET IT
Times cited: 85
Initial experience with alcohol septal ablation using a novel magnetic navigation system. Journal of interventional cardiology. 2007 Academic Article GET IT
Times cited: 6
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Academic Article GET IT
Times cited: 42
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. American heart journal. 2007 Academic Article GET IT
Times cited: 17
Platelet reactivity among Asian Indians and Caucasians. Platelets. 2007 Academic Article GET IT
Times cited: 11
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007 Academic Article GET IT
Times cited: 312
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. American heart journal. 2007 Academic Article GET IT
Times cited: 69
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. European heart journal. 2007 Academic Article GET IT
Times cited: 56
Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. Journal of thrombosis and haemostasis : JTH. 2007 Academic Article GET IT
Times cited: 204
Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. Journal of thrombosis and thrombolysis. 2007 Academic Article GET IT
Times cited: 20
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2007 Academic Article GET IT
Times cited: 105
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. American heart journal. 2007 Academic Article GET IT
Times cited: 23
Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2007 Information Resource GET IT
Times cited: 125
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. American heart journal. 2006 Academic Article GET IT
Times cited: 76
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Academic Article GET IT
Times cited: 166
Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. The American journal of cardiology. 2006 Academic Article GET IT
Times cited: 16
Measuring troponin elevation after percutaneous coronary intervention: ready for prime time?. Journal of the American College of Cardiology. 2006 Editorial Article GET IT
Times cited: 3
Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thrombosis and haemostasis. 2006 Academic Article GET IT
Times cited: 79
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. American heart journal. 2006 Academic Article GET IT
Times cited: 125
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). The American journal of cardiology. 2006 Academic Article GET IT
Times cited: 43
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. American heart journal. 2006 Academic Article GET IT
Times cited: 27
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. American heart journal. 2006 Academic Article GET IT
Times cited: 14
Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention. Coronary artery disease. 2006 Academic Article GET IT
Times cited: 2
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). The American journal of cardiology. 2006 Academic Article GET IT
Times cited: 28
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thrombosis research. 2006 Academic Article GET IT
Times cited: 139
Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thrombosis and haemostasis. 2006 Academic Article GET IT
Times cited: 18
Percutaneous myocardial laser revascularisation may not be effective in severe angina: Commentary. Evidence-based Cardiovascular Medicine. 2006 Article GET IT
Therapeutic strategies for cardiogenic shock, 2006. Current treatment options in cardiovascular medicine. 2006 Academic Article GET IT
Initial experience with a magnetic navigation system for percutaneous coronary intervention in complex coronary artery lesions. Journal of the American College of Cardiology. 2006 Academic Article GET IT
Times cited: 58
Is aspirin resistance valid?. Future cardiology. 2006 Editorial Article GET IT
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. Journal of the American College of Cardiology. 2005 Academic Article GET IT
Times cited: 439
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005 Academic Article GET IT
Times cited: 59
Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. American heart journal. 2005 Academic Article GET IT
Times cited: 28
The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. Heart (British Cardiac Society). 2005 Editorial Article GET IT
Times cited: 12
Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. Journal of vascular research. 2005 Academic Article GET IT
Times cited: 42
Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?. Nature clinical practice. Cardiovascular medicine. 2005 Article GET IT
Resistance to antiplatelet therapy. Current cardiology reports. 2005 Information Resource GET IT
Times cited: 15
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. Journal of the American College of Cardiology. 2005 Academic Article GET IT
Times cited: 40
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. The American journal of cardiology. 2005 Academic Article GET IT
Times cited: 2
Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model. Journal of thrombosis and thrombolysis. 2005 Academic Article GET IT
Times cited: 28
Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2005 Academic Article GET IT
Times cited: 28
Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arteriosclerosis, thrombosis, and vascular biology. 2005 Academic Article GET IT
Times cited: 61
Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. Journal of thrombosis and thrombolysis. 2005 Academic Article GET IT
Times cited: 31
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Academic Article GET IT
Times cited: 496
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Journal of the American College of Cardiology. 2004 Academic Article GET IT
Times cited: 33
Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. Journal of clinical pharmacology. 2004 Academic Article GET IT
Times cited: 25
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004 Academic Article GET IT
Times cited: 358
Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. Journal of thrombosis and thrombolysis. 2004 Academic Article GET IT
Times cited: 57
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. American heart journal. 2004 Academic Article GET IT
Times cited: 9
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. The American journal of cardiology. 2004 Academic Article GET IT
Times cited: 23
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 Academic Article GET IT
Times cited: 710
Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. The American journal of cardiology. 2004 Academic Article GET IT
Times cited: 45
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. American heart journal. 2004 Academic Article GET IT
Times cited: 37
Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. Journal of the American College of Cardiology. 2004 Editorial Article GET IT
Times cited: 10
Acute myocardial infarction: clinical characteristics, management and outcome in a university medical centre in a developing Middle Eastern country. The Canadian journal of cardiology. 2004 Academic Article GET IT
Times cited: 11
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. The Canadian journal of cardiology. 2004 Academic Article GET IT
Times cited: 1
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). The American journal of cardiology. 2004 Academic Article GET IT
Times cited: 200
Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the American College of Cardiology. 2004 Academic Article GET IT
Times cited: 46
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation. 2004 Academic Article GET IT
Times cited: 33
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. Journal of thrombosis and haemostasis : JTH. 2004 Academic Article GET IT
Times cited: 44
Patient-specific antiplatelet therapy. Journal of thrombosis and thrombolysis. 2004 Information Resource GET IT
Times cited: 1
Therapeutic Strategies for Cardiogenic Shock. Current treatment options in cardiovascular medicine. 2004 Academic Article GET IT
Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clinical pharmacology and therapeutics. 2004 Academic Article GET IT
Times cited: 6
Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2004 Information Resource GET IT
Times cited: 9
A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. Journal of the American College of Cardiology. 2003 Academic Article GET IT
Times cited: 226
Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. The Journal of pharmacology and experimental therapeutics. 2003 Academic Article GET IT
Times cited: 39
Arterial thrombosis for the interventional cardiologist: from adhesion molecules and coagulation factors to clinical therapeutics. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2003 Information Resource GET IT
Times cited: 9
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. Journal of the American College of Cardiology. 2003 Academic Article GET IT
Times cited: 46
Bivalirudin, thrombin and platelets: clinical implications and future directions. The Journal of invasive cardiology. 2003 Information Resource GET IT
Times cited: 5
Platelet abnormalities in diabetes mellitus. Coronary artery disease. 2003 Information Resource GET IT
Times cited: 25
Combination therapy for acute myocardial infarction: will it survive?. Journal of the American College of Cardiology. 2003 Editorial Article GET IT
Times cited: 2
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Academic Article GET IT
Times cited: 1042
Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice. The Journal of invasive cardiology. 2003 Academic Article GET IT
Times cited: 2
Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thrombosis research. 2003 Academic Article GET IT
Times cited: 40
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. Journal of the American College of Cardiology. 2002 Academic Article GET IT
Times cited: 57
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. Journal of the American College of Cardiology. 2002 Academic Article GET IT
Times cited: 42
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. The American journal of medicine. 2002 Academic Article GET IT
Times cited: 128
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 Academic Article GET IT
Times cited: 82
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). American heart journal. 2002 Academic Article GET IT
Antiplatelet therapy and coronary interventions: childhood friends or permanent partners?. Journal of interventional cardiology. 2002 Academic Article GET IT
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. American heart journal. 2002 Academic Article GET IT
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. American heart journal. 2002 Academic Article GET IT
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clinical pharmacology and therapeutics. 2002 Academic Article GET IT
Times cited: 20
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002 Academic Article GET IT
Times cited: 552
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002 Academic Article GET IT
Times cited: 102
Antiplatelet therapy and coronary interventions: childhood friends or permanent partners?. Journal of interventional cardiology. 2002 Article GET IT
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. American heart journal. 2002 Academic Article GET IT
Times cited: 66
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European heart journal. 2002 Academic Article GET IT
Times cited: 35
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. American heart journal. 2002 Academic Article GET IT
Times cited: 18
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). The American journal of cardiology. 2001 Academic Article GET IT
Times cited: 69
Abciximab readministration: results of the ReoPro Readministration Registry. Circulation. 2001 Academic Article GET IT
Times cited: 130
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001 Academic Article GET IT
Times cited: 50
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001 Academic Article GET IT
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current controlled trials in cardiovascular medicine. 2001 Academic Article GET IT
Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current controlled trials in cardiovascular medicine. 2001 Academic Article GET IT
Low-molecular-weight heparins. The Journal of invasive cardiology. 2001 Academic Article GET IT
Times cited: 1
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (London, England). 2001 Academic Article GET IT
Times cited: 297
Dalteparin in combination with abciximab during percutaneous coronary intervention. American heart journal. 2001 Academic Article GET IT
Times cited: 88
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation. 2000 Academic Article GET IT
Times cited: 57
Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions. The Journal of invasive cardiology. 2000 Academic Article GET IT
Times cited: 15
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2000 Academic Article GET IT
Times cited: 64
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. American heart journal. 2000 Academic Article GET IT
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. The Annals of thoracic surgery. 2000 Academic Article GET IT
Times cited: 66
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Academic Article GET IT
Times cited: 66
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. American heart journal. 2000 Academic Article GET IT
Times cited: 42
A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. The American journal of cardiology. 2000 Academic Article GET IT
Times cited: 13
Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation. 2000 Academic Article GET IT
Times cited: 44
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000 Academic Article GET IT
Times cited: 102
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. Journal of thrombosis and thrombolysis. 2000 Academic Article GET IT
Times cited: 23
Redefining medical treatment in the management of unstable angina. The American journal of medicine. 2000 Information Resource GET IT
Times cited: 54
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation. 2000 Academic Article GET IT
Times cited: 438
Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro. Journal of thrombosis and thrombolysis. 2000 Academic Article GET IT
Times cited: 5
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (London, England). 1999 Academic Article GET IT
Times cited: 328
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999 Academic Article GET IT
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. The American journal of cardiology. 1999 Academic Article GET IT
Times cited: 83
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. The New England journal of medicine. 1999 Academic Article GET IT
Times cited: 384
Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?. Circulation. 1999 Information Resource GET IT
Times cited: 208
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 1999 Academic Article GET IT
Times cited: 141
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Academic Article GET IT
Times cited: 709
GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology. Drugs in R&D. 1999 Information Resource GET IT
Times cited: 9
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 1999 Academic Article GET IT
Times cited: 156
Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. Journal of the American College of Cardiology. 1999 Academic Article GET IT
Times cited: 71
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. American heart journal. 1999 Academic Article GET IT
Times cited: 11
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. Journal of the American College of Cardiology. 1998 Academic Article GET IT
Times cited: 116
Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation. 1998 Academic Article GET IT
Times cited: 102
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998 Academic Article GET IT
Times cited: 203
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 1998 Academic Article GET IT
Times cited: 90
Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow. American heart journal. 1998 Academic Article GET IT
Times cited: 43
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. The American journal of cardiology. 1998 Academic Article GET IT
Times cited: 21
Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 1998 Academic Article GET IT
Times cited: 113
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation. 1998 Academic Article GET IT
Times cited: 111
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. The American journal of cardiology. 1998 Academic Article GET IT
Times cited: 22
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology. 1998 Academic Article GET IT
Times cited: 59
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists. Coronary artery disease. 1998 Information Resource GET IT
Times cited: 16
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. American heart journal. 1998 Academic Article GET IT
Times cited: 10
Does the early hazard phenomenon exist? Do the GUSTO findings prove or disprove?. Circulation. 1997 Letter GET IT
Times cited: 1
Physicians' use of heparin following thrombolytic therapy: An international perspective. Journal of Thrombosis and Thrombolysis. 1997 Article GET IT
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation. 1997 Academic Article GET IT
Times cited: 65
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997 Academic Article GET IT
Times cited: 429
Use of bare-mounted Palmaz-Schatz stents employing the stent saddle technique on the delivery balloon: a single center experience. Catheterization and cardiovascular diagnosis. 1997 Academic Article GET IT
Times cited: 4
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology. 1997 Academic Article GET IT
Times cited: 210
Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clinical cardiology. 1997 Editorial Article GET IT
Times cited: 23
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997 Academic Article GET IT
Times cited: 390
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). The American journal of cardiology. 1997 Academic Article GET IT
Times cited: 27
Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). The American journal of cardiology. 1997 Academic Article GET IT
Times cited: 109
Effects of Integrelin on platelet function in flow models of arterial thrombosis. Journal of cardiovascular pharmacology. 1997 Academic Article GET IT
Times cited: 25
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. The American journal of cardiology. 1997 Academic Article GET IT
Times cited: 129
Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. The American journal of cardiology. 1996 Academic Article GET IT
Times cited: 4
Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine. Coronary artery disease. 1996 Academic Article GET IT
Times cited: 11
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. The New England journal of medicine. 1996 Academic Article GET IT
Times cited: 969
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996 Academic Article GET IT
Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation. 1996 Academic Article GET IT
Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Coronary artery disease. 1996 Information Resource GET IT
Times cited: 3
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA. 1996 Academic Article GET IT
Times cited: 306
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Journal of the American College of Cardiology. 1996 Academic Article GET IT
Times cited: 198
Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). The American journal of cardiology. 1996 Academic Article GET IT
Times cited: 47
Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial. The Journal of invasive cardiology. 1996 Academic Article GET IT
Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 1996 Academic Article GET IT
Times cited: 28
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. The American journal of cardiology. 1995 Academic Article GET IT
Times cited: 188
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Journal of the American College of Cardiology. 1995 Academic Article GET IT
Times cited: 153
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Journal of the American College of Cardiology. 1995 Academic Article GET IT
Times cited: 302
Platelets and platelet inhibitors in acute myocardial infarction. Cardiology clinics. 1995 Information Resource GET IT
Times cited: 10
Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. Journal of the American College of Cardiology. 1995 Academic Article GET IT
Times cited: 178
Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 1995 Academic Article GET IT
Times cited: 88
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 1995 Academic Article GET IT
Times cited: 269
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology. 1995 Academic Article GET IT
Times cited: 116
Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation. 1995 Academic Article GET IT
Times cited: 76
Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995 Academic Article GET IT
Times cited: 83
Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation. 1995 Academic Article GET IT
Times cited: 473
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation. 1994 Academic Article GET IT
Times cited: 117
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a "new diagnostic mind-set". Circulation. 1994 Letter GET IT
Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. The American journal of cardiology. 1994 Academic Article GET IT
Times cited: 48
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994 Academic Article GET IT
Times cited: 407
Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Circulation. 1994 Academic Article GET IT
Times cited: 43
Heterotopic heart transplantation: catheterization, endomyocardial biopsy, and coronary angiography of the donor heart. Catheterization and cardiovascular diagnosis. 1994 Academic Article GET IT
Times cited: 1
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Journal of the American College of Cardiology. 1994 Academic Article GET IT
Times cited: 255
Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction. American heart journal. 1994 Academic Article GET IT
Times cited: 4
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation. 1994 Academic Article GET IT
Times cited: 171
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'. Circulation. 1994 Information Resource GET IT
Times cited: 100
Is intravascular ultrasound better than quantitative coronary arteriography to assess cardiac allograft arteriopathy?. Catheterization and cardiovascular diagnosis. 1994 Academic Article GET IT
Times cited: 12
What are the implications of cardiac infection with cytomegalovirus before heart transplantation?. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1994 Academic Article GET IT
Times cited: 16
Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. Journal of the American College of Cardiology. 1993 Academic Article GET IT
Times cited: 61
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. The American journal of cardiology. 1993 Academic Article GET IT
Times cited: 44
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The New England journal of medicine. 1993 Academic Article GET IT
Times cited: 3439
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. Journal of the American College of Cardiology. 1993 Academic Article GET IT
Times cited: 315
Magnetic resonance imaging for assessment of tissue rejection after heterotopic heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1993 Academic Article GET IT
Times cited: 23
Transesophageal echocardiographic demonstration of right coronary artery-to-coronary sinus fistula in a heart transplant recipient. 1993 GET IT
Times cited: 2
Effectiveness of videotaped dietary instruction for patients hospitalized with cardiovascular disease. Journal of the American Dietetic Association. 1992 Academic Article GET IT
Times cited: 2
Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performance. Journal of the American College of Cardiology. 1992 Academic Article GET IT
Times cited: 200
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. Journal of the American College of Cardiology. 1992 Academic Article GET IT
Times cited: 66
Rotational ablation of coronary artery lesions using single, large burrs. Catheterization and cardiovascular diagnosis. 1992 Academic Article GET IT
Times cited: 10
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Journal of the American College of Cardiology. 1992 Academic Article GET IT
Times cited: 43
Coronary angiography after heart transplantation: should perioperative study be the "gold standard"?. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1992 Academic Article GET IT
Times cited: 10
The relationship of soluble interleukin-2 receptor levels to allograft arteriopathy after heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1992 Academic Article GET IT
Times cited: 17
Interobserver variability in grading of coronary arterial narrowings using the American College of Cardiology/American Heart Association grading criteria. The American journal of cardiology. 1992 Academic Article GET IT
Times cited: 32
Aspirin, Heparin, and Other Ancillary Therapies Following Thrombolysis. Journal of Interventional Cardiology. 1992 Article GET IT
Diagnosis of ischemic heart disease with adenosine echocardiography. Journal of the American College of Cardiology. 1991 Academic Article GET IT
Times cited: 70
Elevated soluble interleukin-2 receptor levels early after heart transplantation and long-term survival and development of coronary arteriopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1991 Academic Article GET IT
Times cited: 16
Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction. Journal of the American College of Cardiology. 1991 Academic Article GET IT
Times cited: 16
Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation. Transplantation. 1991 Academic Article GET IT
Times cited: 16
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. The New England journal of medicine. 1990 Academic Article GET IT
Times cited: 346
Percutaneous transluminal coronary angioplasty in octogenarians. Annals of internal medicine. 1990 Academic Article GET IT
Times cited: 64
Percutaneous transluminal coronary angioplasty: is what we see what we get?. Journal of the American College of Cardiology. 1990 Editorial Article GET IT
Times cited: 2
Factors influencing the outcome of balloon aortic valvuloplasty in the elderly. American heart journal. 1990 Academic Article GET IT
Times cited: 10
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. Circulation. 1990 Academic Article GET IT
Times cited: 58
Lack of diurnal variation in the onset of non-Q wave infarction. Circulation. 1990 Academic Article GET IT
Times cited: 46
Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA. American heart journal. 1990 Academic Article GET IT
Times cited: 78
Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts. The American journal of cardiology. 1989 Academic Article GET IT
Times cited: 14
Helicopter transport of patients with acute myocardial infarction. Texas medicine. 1988 Academic Article GET IT
Times cited: 4
Thrombolytic treatment for acute myocardial infarction. Texas medicine. 1988 Information Resource GET IT
Relation of left ventricular dilation during acute myocardial infarction to systolic performance, diastolic dysfunction, infarct size and location. The American journal of cardiology. 1988 Academic Article GET IT
Times cited: 49
Arteriographic demonstration of coronary artery spasm during thrombolysis. Texas Heart Institute journal. 1988 Academic Article GET IT
Percutaneous transluminal coronary angioplasty in the treatment of patients with unstable angina and acute myocardial infarction. Problems in Critical Care. 1988 Article
Thrombolytic therapy in acute myocardial infarction. Problems in Critical Care. 1988 Article
[Prognostic significance of initial blood glucose levels in acute myocardial infarction]. Harefuah. 1982 Academic Article GET IT
Anticoagulant therapy in acute myocardial infarction: demonstration of a selection bias in a retrospective study. Thrombosis research. 1980 Academic Article GET IT
Times cited: 2

more ...

less ...

Background

education and training

M.D., Columbia University College of Physicians and Surgeons 1981
A.B., Princeton University 1977

Contact

full name

Neal Kleiman

VIVO Weill Cornell Medical College

Neal Kleiman Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name